In this issue:
Adalimumab + methotrexate for inadequately controlled PsA
Secukinumab and patient-reported outcomes in active PsA
Mavrilimumab for giant cell arteritis
Olokizumab + methotrexate in inadequately controlled RA
Ustekinumab for active SLE
Cytokine inhibitor therapy and immune response against SARS-CoV-2
B-cell reconstitution and COVID-19 vaccine responsiveness after rituximab
Alemtuzumab for refractory primary systemic vasculitis
Mesenchymal stem cell therapy for knee OA
Rituximab and hypogammaglobulinaemia in childhood-onset rheumatic diseases
T-cell response after COVID-19 vaccination with belimumab and rituximab
Clinical course of SARS-CoV-2 infection in children under biologic therapy
Pregnancy outcomes after exposure to certolizumab pegol
Biologic agents for OA
Please login below to download this issue (PDF)